PeerView Gastroenterology CME/CNE/CPE Video Podcast - Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

12/28/21 • 68 min

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.

Previous Episode

undefined - Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, and locoregional combinations with systemic therapies, across the HCC disease spectrum, Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors, Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities.

Next Episode

undefined - Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Go online to PeerView.com/SQH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in eosinophilic esophagitis discuss the diagnosis of pediatric and adult EoE, the current standard of care, and novel and emerging treatments that may be the future of EoE management. Upon completion of this CE activity, participants will be able to: Differentiate signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to facilitate early diagnosis and minimize complications caused by uncontrolled disease, Describe the underlying pathophysiology of EoE and how it correlates to potential treatment targets such as interleukin-4, -13, and -5, Discuss the limitations of the current standard of care for the treatment of EoE, Apply the latest clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.